The chemistry and immunochemistry of blood group A, B, H, and Lewis antigens: Past, present and future

Glycoconjugate Journal

Volumn 17, Issue 7-9, 2000, Pages 531-541

  Lloyd, Kenneth O ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Alkaline elimination; Blood group antigens; Epitopes; Glycolipids; Mucins; Oligosaccharide synthesis; Oligosaccharides; Tumor antigens

Indexed keywords

BLOOD GROUP A ANTIGEN; BLOOD GROUP B ANTIGEN; BLOOD GROUP O ANTIGEN; CANCER VACCINE; MUCIN; TUMOR ANTIGEN;

ANTIGEN DETECTION; BLOOD GROUP ABO SYSTEM; BLOOD GROUP LEWIS SYSTEM; BLOOD GROUP SYSTEM; CANCER IMMUNOTHERAPY; CARBOHYDRATE ANALYSIS; EPITOPE MAPPING; HUMAN; HUMAN CELL; IMMUNOCHEMISTRY; PRIORITY JOURNAL; REVIEW; STRUCTURE ANALYSIS;

ABO BLOOD-GROUP SYSTEM; AMINO ACID SEQUENCE; AUTOBIOGRAPHY; CARBOHYDRATE SEQUENCE; GLYCOLIPIDS; GLYCOPROTEINS; HISTORY, 20TH CENTURY; HUMANS; IMMUNOCHEMISTRY; LEWIS BLOOD-GROUP SYSTEM; MOLECULAR SEQUENCE DATA; MUCINS; NEOPLASMS; OLIGOSACCHARIDES; POLYSACCHARIDES; UNITED STATES;

EID: 0034443638     PISSN: 02820080     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1011066308591     Document Type: Review

References (58)

1. 1 Hakomori S, Antigen structure and genetic basis of histo-blood groups A, B and O: their changes associated with human cancer, Biochim Biophys Acta Gen Subj 1473, 247-66 (1999).
2. 2 Greenwell P, Blood group antigens: molecules seeking a function? Glycoconjugate J 14, 159-73 (1997).
3. 3 Lloyd KO, Philip Levine award lecture. Blood group antigens as markers for normal differentiation and malignant change in human tissues, Am J Clin Pathol 87, 129-39 (1987).
4. 4 Yosida K, Über die gruppenspezifischen unterschiede der transsudate, exsudate, sekrete, exkrete, organextrakte und organzellen des menschen und ihre rechtsmedizinischen, Z Gesamte Exp Med 63, 331-9 (1928).
5. 5 Kabat EA, Blood Group Substances: Their chemistry and immunochemistry (Academic Press, Inc., New York, 1956), pp. 1-330.
6. 6 Watkins WM, Morgan WTJ, Neutralization of the anti-H agglutinin in eel serum by simple sugars, Nature 169, 825-6 (1952).
7. 7 Watkins WM, Morgan WTJ, Specific inhibition studies related to the Lewis blood-group system, Nature 188, 1038-40 (1957).
8. 8 Watkins WM, Morgan WTJ, Further observations on the inhibition of blood-group specific serological reactions by simple sugars of known structure, Vox Sang 7, 129-50 (1962).
9. a substances: possible sugar sequences in the carbohydrate chains, Nature 200, 532-4 (1963).
10. 10 Lloyd KO, Kabat EA, Some products of the degradation of blood group substances by alkaline borohydride, Biochem Biophys Res Commun 16, 385-90 (1964).
11. 11 Lloyd KO, Kabat EA, Layug EJ, Gruezo F, Immunochemical studies on brood groups. XXXIV. Structures of some oligosaccharides produced by alkaline degradation of blood group A, B, and H substances, Biochemistry 5, 1489-501 (1966).
12. 12 Lloyd KO, Beychok S, Kabat EA, Immunochemical studies on blood groups, XXXVII. The structures of difucosyl and other oligosaccharides produced by alkaline degradation of blood group A, B, and H substances. Optical rotatory dispersion and circular dichroism spectra of these oligosaccharides, Biochemistry 6, 1448-54 (1967).
13. b substances, Biochemistry 7, 2976-90 (1968).
14. b substances, Proc Natl Acad Sci (USA) 61, 1470-7 (1968).
15. 15 Lloyd KO, Kabat EA, Immunochemical studies on blood groups, XXXVI. The nature of the unsaturated residue in some oligosaccharides produced by the action of sodium hydroxide-sodium borohydride on blood-group A, B, and H substances, Carbohydr Res 4, 165-77 (1967).
16. 16 Fukuda M, Tsuboi S, Mucin-type O-glycans and leukosialin, Biochim Biophys Acta 1455, 205-17 (1999).
17. 17 Lloyd KO, Burchell J, Kudryashov V, Yin BWT, Taylor-Papadimitriou J, Comparison of O-linked carbohydrate chains in MUC-1 mucin from normal breast epithelial cell lines and breast carcinoma cell lines, J Biol Chem 271, 33325-34 (1996).
18. 18 Lloyd KO, Kabat EA, Beychok S, Immunochemical studies on blood groups. XLIII. The interaction of blood group substances from various sources with a plant lectin, concanavalin A, J Immunol 102, 1354-62 (1969).
19. 19 Nakayama J, Yeh JC, Misra AK, Ito S, Katsuyama T, Fukuda M, Expression cloning of a human α1,4-N-acetylglucosaminyltransferase that forms GlcNAc α1 → Galβ → R, a glycan specifically expressed in the gastric gland mucous cell-type mucin, Proc Natl Acad Sci USA 96, 8991-6 (1999).
20. 20 Iyer RN, Carlson DM, Alkaline borohydride degradation of blood group H substance, Arch Biochem Biophys 142, 101-5 (1971).
21. 21 Rovis L, Anderson B, Kabat EA, Gruenzo F, Liao J, Structures of oligosaccharides produced by base-borohydride degradation of human ovarian cyst blood group H, Le-b and Le-a active glycoproteins, Biochemistry 12, 5340-54 (1973).
22. 22 Wu AM, Kabat EA, Nilsson B, Zopf DA, Gruezo FG, Liao J, Immunochemical studies on blood groups. Purification and characterization of radioactive 3H-reduced di-to hexasaccharides produced by alkaline beta-elimination-borohydride 3H reduction of Smith degraded blood group A active glycoproteins, J Biol Chem 259, 7178-86 (1984).
23. 23 Dua VK, Rao BNN, Wu S-S, Dube VE, Bush CA, Characterization of oligosaccharide alditols from ovarian cyst mucin glycoproteins of blood group A using high pressure liquid chromatography (HPLC) and high field 1-H NMR spectroscopy, J Biol Chem 261, 1599-608 (1986).
24. 24 Derevitskaya V, Arbatsky NP, Kochetkov NK, The structure of carbohydrate chains of brood-group substance: Isolation and elucidation of the structure of higher oligosaccharides from blood-group substance H, Eur J Biochem 86, 423-37 (1978).
25. 25 Watkins WM, Genetic regulation of the structure of blood-group-specific glycoproteins, Biochem Soc Symp 40, 125-46 (1974).
26. 26 Kabat EA, Bassett EW, Pryzwansky K, Lloyd KO, Kaplan ME, Layug EJ, Immunochemical studies on blood groups, XXXIII. The effects of alkaline borohydride and of alkali on blood group A, B, and H substances, Biochemistry 4, 1632-8 (1965).
27. 27 Gendler SJ, Spicer AP, Epithelial mucin genes, Annu Rev Physiol 57, 607-34 (1995).
28. 28 Taylor-Papadimitriou J, Burchell J, Miles DW, Dalziel M, MUC1 and cancer, Biochim Biophys Acta 1455, 301-13 (1999).
29. 29 Lloyd KO, Yin BW, Tempst P, Erdjument-Bromage H, MUC-6 mucin is a major component of 'blood group substance' from human ovarian cyst fluid, Biochim Biophys Acta Gen Subj 1474, 410-4 (2000).
30. 30 Bobek LA, Tsai H, Biesbrock AR, Levine MJ, Molecular cloning, sequence, and specificity of expression of the gene encoding the low molecular weight human salivary mucin (MUC7), J Biol Chem 268, 20563-9 (1993).
31. 31 Hakomori S, Blood group ABH and li antigens of human erythrocytes: chemistry, polymorphism, and their developmental change, Semin Hematol 18, 39-62 (1981).
32. 32 Marcus DM, Cass L, Glycosphingolipids with Lewis blood group activity: Uptake by human erythrocytes, Science 164, 553-5 (1969).
33. 33 Feizi T, Childs RA, Hakomori SI, Powell ME, Blood-group-li-active gangliosides of human erythrocyte membranes, Biochem J 173, 245-54 (1978).
34. 34 Furukawa K, Mattes MJ, Lloyd KO, A1 and A2 erythrocytes can be distinguished by reagents that do not detect structural differences between the two cell types, J Immunol 135, 4090-4 (1985).
35. 35 Danishefsky SJ, Bilodeau MT, Glycals in organic synthesis: The evolution of comprehensive strategies for the assembly of oligosaccharides and glycoconjugates of biological consequence, Angew Chem Int Ed Engl 35, 1380-419 (1996).
36. 36 Seeberger PH, Danishefsky SJ, Solid-phase synthesis of oligosaccharides and glycoconjugates by the glycal assembly method: a five year retrospective, Accounts Chem Res 31, 685-95 (1998).
37. b blood group determinants and of H-type I and H-type II oligosaccharides, J Am Chem Soc 117, 5701-11 (1995).
38. 38 Glunz PW, Hintermann 5, Schwarz JB, Kuduk SD, Chen XT, Williams LJ, Sames D, Danishefsky SJ, Kudryashov V, Lloyd KO, Probing cell surface "glyco-architecture" through total synthesis. Immunological consequences of a human blood group determinant in a clustered mucin-like context, J Am Chem Soc 121, 10636-7 (1999).
39. 39 Lloyd KO, Furukawa K, Biosynthesis and functions of gangliosides: recent advances, Glycoconjugate J 15, 627-36 (1998).
40. b, X, and Y blood group antigens in human colonic tumors and normal tissue and in human tumor-derived cell lines, Cancer Res 46, 1553-61 (1986).
41. 41 Lloyd KO, Larson G, Stromberg N, Thurin J, Karlsson KA, Mouse monoclonal antibody F-3 recognizes the difucosyl type-2 blood group structure, Immunogenetics 17, 537-41 (1983).
42. 42 Cordon Cardo C, Lloyd KO, Finstad CL, McGroarty ME, Reuter VE: Bander NH, Old LJ, Melamed MR, Immunoanatomic distribution of blood group antigens in the human urinary tract. Influence of secretor status, Lab Invest 55, 444-54 (1986).
43. 43 Magnani JL, Nilsson B, Brockhaus M, Zopf D, Steplewski Z, Koprowski H, Ginsburg V, A monoclonal antibody-defined antigen associated with gastrointestinal cancer is a ganglioside containing sialylated lacto-N-fucopentaose II, J Biol Chem 257, 14365-9 (1982).
44. x as a new tumor-associated antigen, Cancer Res 44, 5279-85 (1984).
45. 45 Rosen SD, Bertozzi CR, The selectins and their ligands, Curr Opin Cell Biol 6, 663-73 (1994).
46. 46 Springer GF, T and Tn, general carcinoma autoantigens, Science 224, 1198-206 (1984).
47. 47 Itzkowitz SH, Yuan M, Montgomery CK, Kjeldsen T, Takahashi HK, Bigbee WL, Kim YS, Expression of Tn, sialosyl-Tn, and T antigens in human colon cancer, Cancer Res 49, 197-204 (1989).
48. 48 Zhang S, Zhang HS, Cordon-Cardo C, Reuter VE, Singhal AK, Lloyd KO, Livingston PO, Selection of tumor antigens as targets for immune attack using immunohistochemistry. 2. Blood group-related antigens, Int J Cancer 73, 50-6 (1997).
49. 49 Trail PA, Willner D, Lasch SJ, Henderson AJ, Hofstead S, Casazza AM, Firestone RA, Hellstrom I, Hellstrom KE, Cure of xenografted human carcinomas by BR96-doxorubicin immunoconjugates, Science 261, 212-5 (1994).
50. 50 Tolcher AW, Sugarman S, Gelmon KA, Cohen R, Saleh M, Isaacs C, Young L, Healey D, Onetto N, Slichenmyer W, Randomized phase II study of BR96-doxorubicin conjugate in patients with metastatic breast cancer, J Clin Oncol 17, 478-84 (1999).
51. y antibodies generated against synthetic and natural Ley determinants, Proc Natl Acad Sci USA 91, 12957-61 (1994).
52. 52 Livingston PO, Ragupathi G, Carbohydrate vaccines that induce antibodies against cancer .2. Previous experience and future plans, Cancer Immunol Immunother 45, 10-9 (1997).
53. 53 Tai T, Cahan LD, Tsuchida T, Saxton RE, Irie RF, Morton DL, Immunogenicity of melanoma-associated gangliosides in cancer patients, Int J Cancer 35, 607-12 (1985).
54. y-protein conjugate vaccine: A phase 1 trial, Int J Cancer 87, 79-85 (2000).
55. 55 Slovin SF, Ragupathi G, Adluri S, Ungers G, Terry K, Kim S, Spassova M, Bornmann WG, Fazzari M, Dantis L, Olkiewicz K, Lloyd KO, Livingston PO, Danishefsky SJ, Scher HI, Carbohydrate vaccines in cancer: Immunogenicity of a fully synthetic globo H hexasaccharide conjugate in man, Proc Natl Acad Sci USA 96, 5710-5 (1999).
56. 56 Adluri S, Helling F, Ogata S, Zhang S, Itzkowitz SH, Lloyd KO, Livingston PO, Immunogenicity of synthetic TF-KLH (keyhole limpet hemocyanin) and sTn-KLH conjugates in colorectal carcinoma patients, Cancer Immunol Immunother 41, 185-92 (1995).
57. x and related structures as adhesion molecules, Histochem J 24, 771-6 (1992).
58. y/H: An endothelial-selective, cytokine-inducible, angiogenic mediator, J Immunol 164, 4868-77 (2000).